RNR2B Antibody

What is RXR beta/NR2B2 and what cellular functions does it regulate?

RXR beta/NR2B2 (Retinoid X Receptor beta) is a nuclear receptor that functions as a transcription factor belonging to the nuclear receptor subfamily 2, group B, member 2. It plays crucial roles in regulating gene expression in response to various ligands. The protein is involved in several biological processes including development, metabolism, and cell differentiation. RXR beta/NR2B2 is also known by several alternative names including DAUDI6, H-2RIIBP, RCoR-1, and RXRB as documented in product datasheets .

The protein primarily functions through formation of heterodimers with other nuclear receptors, enabling the regulation of specific gene expression patterns. It can bind to DNA response elements as either a homodimer or heterodimer, offering versatility in transcriptional regulation mechanisms. When selecting antibodies for RXR beta/NR2B2 research, consider which protein domains and functions are relevant to your research question.

What applications are RXR beta/NR2B2 antibodies commonly used for in research?

RXR beta/NR2B2 antibodies are utilized across several experimental applications including:

• Western blotting (WB): For detecting and quantifying RXR beta/NR2B2 protein expression in cell or tissue lysates

• Immunoprecipitation (IP): For isolating RXR beta/NR2B2 and its interacting partners from complex protein mixtures

• Chromatin immunoprecipitation (ChIP): For studying DNA-protein interactions

• Immunofluorescence/Immunohistochemistry: For visualizing the subcellular localization and tissue distribution

Commercial antibodies like the Human RXR beta/NR2B2 Antibody (PP-H7341-00) are validated for specific applications such as Western blot and immunoprecipitation as indicated in product information . For each application, the optimal antibody concentration should be determined empirically, following manufacturer recommendations as a starting point.

How do I determine the optimal conditions for RXR beta/NR2B2 antibody use?

Determining optimal conditions requires systematic optimization rather than relying solely on manufacturer recommendations:

• Start with the manufacturer's recommended dilution and conditions

• Test a range of dilutions (typically 2-fold or 5-fold dilution series)

• Include appropriate positive controls (cell lines or tissues known to express RXR beta/NR2B2)

• Evaluate signal-to-noise ratio, background levels, and specificity

• Consider the abundance of RXR beta/NR2B2 in your specific samples - nuclear proteins often require specialized extraction methods

For the Human RXR beta/NR2B2 Antibody (PP-H7341-00), specific recommendations for Western blot and immunoprecipitation applications are provided in the product datasheet . Remember that optimal conditions may vary between batches of antibodies and sample types, so verification is important when changing either variable.

How can I distinguish between specific binding and non-specific interactions when using RXR beta/NR2B2 antibodies?

Distinguishing specific from non-specific binding requires rigorous validation approaches:

• Include multiple controls:

  • Genetic controls (siRNA knockdown of RXR beta/NR2B2)

  • Peptide competition assays where the antibody is pre-incubated with excess immunizing peptide

  • Secondary antibody-only controls

  • Isotype controls using non-relevant antibodies of the same class (mouse IgG2a for PP-H7341-00)

• Use alternative detection methods:

  • Validate findings with multiple antibodies targeting different epitopes of RXR beta/NR2B2

  • Correlate protein detection with mRNA expression

  • Consider functional assays that detect transcriptional activity

• Technical approaches:

  • Optimize blocking conditions to reduce non-specific binding

  • Increase washing stringency for improved signal-to-noise ratio

  • For Western blots, verify the molecular weight matches the expected size of RXR beta/NR2B2

The most robust validation includes demonstrating absence of signal in knockout/knockdown models, which provides definitive evidence of antibody specificity.

What are the experimental challenges when studying RXR beta/NR2B2 heterodimerization with other nuclear receptors?

Studying nuclear receptor heterodimerization presents unique challenges due to the dynamic nature of these interactions:

• Epitope accessibility concerns:

  • Ensure that your antibody's epitope is not masked during heterodimerization

  • Consider using antibodies targeting different regions of RXR beta/NR2B2

• Co-immunoprecipitation (Co-IP) optimization:

  • Use mild lysis conditions to preserve protein-protein interactions

  • Consider cross-linking prior to lysis to stabilize transient interactions

  • Implement appropriate nuclear extraction protocols to ensure efficient recovery of nuclear receptors

  • Include appropriate controls (IgG control, reversed Co-IP)

• Context-dependent interactions:

  • RXR beta/NR2B2 dimerization is influenced by ligands, so consider the presence/absence of relevant ligands

  • Cell type-specific factors may influence heterodimerization efficiency

Recent advances in antibody-based methodologies have improved detection of protein-protein interactions. Studies using cryo-electron microscopy (cryo-EM) have successfully captured images of antibodies bound to receptors, revealing physical mechanisms of interaction that could inform experimental design for nuclear receptor studies .

How can I address contradictory results between different detection methods when using RXR beta/NR2B2 antibodies?

Contradictory results between different detection methods require systematic investigation:

• Protein conformation differences:

  • In Western blotting, proteins are denatured, potentially exposing epitopes that are masked in native conformations used in other methods

  • Consider whether the antibody's epitope is accessible in all experimental conditions

• Method-specific technical factors:

  • Different fixatives and sample preparation techniques can affect epitope recognition

  • Test multiple fixation protocols and extraction methods

  • For immunohistochemistry, evaluate different antigen retrieval approaches

• Specificity verification:

  • Use RXR beta/NR2B2 knockdown as negative control across all methods

  • Peptide competition assays can verify specificity in different techniques

• Data integration:

  • Western blotting detects total protein levels while immunofluorescence reveals spatial distribution

  • Consider these as complementary rather than contradictory approaches

  • Differences may reflect biologically relevant phenomena rather than technical artifacts

When reporting discrepancies in publications, transparently discuss the technical differences and potential biological implications rather than simply selecting the technique that supports your hypothesis.

What are the optimal sample preparation protocols for detecting RXR beta/NR2B2 in nuclear extracts?

Detecting nuclear receptors like RXR beta/NR2B2 requires careful attention to nuclear extraction techniques:

• Nuclear extraction protocol:

  • Use gentle detergent-based methods for initial cell lysis to separate cytoplasmic and nuclear fractions

  • For nuclear extraction buffer, include appropriate salt concentration (typically 400-420 mM NaCl)

  • Add protease inhibitors, phosphatase inhibitors, and reducing agents to prevent degradation and oxidation

  • Consider including specific proteasome inhibitors as nuclear receptors often undergo regulated degradation

• Subcellular fractionation quality control:

  • Verify fractionation efficiency using markers for different cellular compartments

  • Poor separation may lead to misleading results about nuclear receptor distribution

• Sample handling:

  • Process samples quickly and maintain cold temperatures throughout extraction

  • Avoid freeze-thaw cycles which can degrade nuclear proteins

  • For RXR beta/NR2B2 antibodies like PP-H7341-00, storage at -70°C is recommended for the antibody itself, and similar care should be taken with samples

• Quantification considerations:

  • Load equal amounts of nuclear protein (rather than total protein) when comparing samples

  • Consider normalizing to a nuclear-specific housekeeping protein

These protocols should be optimized for your specific cell type or tissue, as nuclear extraction efficiency can vary significantly between different biological samples.

What are effective immunoprecipitation protocols for studying RXR beta/NR2B2 protein interactions?

The Human RXR beta/NR2B2 Antibody (PP-H7341-00) is suitable for immunoprecipitation studies . For optimal results:

• Cell lysis considerations:

  • Use buffers that preserve protein-protein interactions (typically containing 150 mM NaCl, 1% NP-40 or Triton X-100, 50 mM Tris pH 7.4)

  • For nuclear proteins like RXR beta/NR2B2, include a nuclear extraction step before immunoprecipitation

  • Consider mild sonication to shear chromatin if studying chromatin-bound fractions

• Antibody-bead coupling:

  • Pre-couple the antibody to protein A/G beads (for mouse IgG2a antibodies like PP-H7341-00)

  • Determine optimal antibody amount through titration (typically 1-5 μg per immunoprecipitation)

  • Allow sufficient incubation time (overnight at 4°C is often optimal for nuclear protein complexes)

• Washing and elution:

  • Balance between washing stringency and preserving interactions

  • Consider gentle elution methods if subsequent functional assays are planned

• Controls:

  • Include IgG isotype controls processed identically to experimental samples

  • Input samples should always be analyzed alongside IP samples

  • Consider reverse IPs to validate interactions from both perspectives

For detecting co-immunoprecipitated proteins, follow the specific Western blotting recommendations for the antibodies used for detection.

What experimental design considerations are important when using RXR beta/NR2B2 antibodies for ChIP assays?

Chromatin immunoprecipitation (ChIP) with RXR beta/NR2B2 antibodies requires careful consideration:

• Chromatin preparation:

  • Optimize crosslinking conditions (typically 1% formaldehyde for 10-15 minutes)

  • Fine-tune sonication parameters to generate DNA fragments of 200-500 bp

  • Verify fragment size by agarose gel electrophoresis

• Antibody selection:

  • Use ChIP-validated antibodies when possible

  • If using a new antibody like PP-H7341-00 for ChIP, perform extensive validation

  • Consider the epitope location - some epitopes may be masked when the protein is bound to DNA

• Experimental controls:

  • Input chromatin (typically 1-5% of starting material)

  • IgG control immunoprecipitation

  • Positive control regions (known RXR beta/NR2B2 binding sites)

  • Negative control regions (genomic regions not expected to bind RXR beta/NR2B2)

• Analysis considerations:

  • Design primers for qPCR that span known or predicted RXR binding sites

  • For ChIP-seq, include appropriate sequencing controls

  • Analyze data using established statistical methods to identify significant binding sites

Recent advances in antibody development techniques include atomically accurate de novo design approaches, which may eventually provide improved reagents for studying nuclear receptors through ChIP and other techniques .

How should I interpret multiple bands in Western blots when using RXR beta/NR2B2 antibodies?

When encountering multiple bands in Western blots:

• Expected banding pattern:

  • Verify the predicted molecular weight for RXR beta/NR2B2 in your species

  • Confirm this main band in your positive control samples

• Analyzing additional bands:

  • Higher molecular weight bands may represent post-translationally modified forms (phosphorylation, SUMOylation), dimers, or splice variants

  • Lower molecular weight bands may represent degradation products or specific proteolytic fragments

• Validation approaches:

  • Use multiple antibodies targeting different epitopes to confirm specificity

  • Run knockdown controls to identify which bands disappear

  • Perform peptide competition assays to determine which bands are specific

• Technical considerations:

  • Adjust reducing conditions if you suspect disulfide-linked complexes

  • Optimize sample preparation if you suspect incomplete denaturation

  • Try gradient gels for better separation of closely migrating bands

• Documentation practices:

  • When publishing, clearly indicate which band(s) you consider specific and provide evidence

  • Include molecular weight markers alongside your blots

Altered banding patterns may have biological significance in different cell types or disease states, but these observations require rigorous validation.

How can I quantitatively analyze RXR beta/NR2B2 expression data across different experimental conditions?

Quantitative analysis of RXR beta/NR2B2 expression requires careful consideration of normalization and statistical approaches:

• Western blot quantification:

  • Use digital image analysis software that allows for background subtraction

  • Define regions of interest consistently across all samples

  • Normalize to appropriate loading controls:

    • For total cell lysates: housekeeping proteins like GAPDH

    • For nuclear extracts: nuclear-specific proteins like Lamin B or Histone H3

  • Consider the linear dynamic range of your detection method

• qPCR analysis for mRNA expression:

  • Select stable reference genes validated for your experimental conditions

  • Use multiple reference genes for more robust normalization

  • Apply appropriate qPCR normalization methods

• Statistical approaches:

  • Perform appropriate statistical tests based on your experimental design

  • Report effect sizes alongside p-values

  • Consider biological vs. technical replicates in your analysis

• Visualization considerations:

  • Present normalized data with clear indication of variability

  • Include individual data points alongside means when sample size is small

  • Use consistent scaling when comparing across experimental conditions

• Special considerations for RXR beta/NR2B2:

  • As a nuclear receptor, RXR beta/NR2B2 expression may show smaller changes than its target genes

  • Consider analyzing nuclear localization separately from total expression

  • Correlate protein expression with functional readouts (target gene expression)

What are best practices for validating RXR beta/NR2B2 antibody specificity across different applications?

Validating antibody specificity across applications requires comprehensive approaches:

• Application-specific validation:

  • An antibody that works well in Western blot may not be suitable for immunoprecipitation

  • Validate each application separately using appropriate controls

  • Document validation results for each application

• Cross-validation strategies:

  • Use orthogonal methods to confirm antibody specificity

  • Compare results from antibodies targeting different epitopes

  • Correlate with mRNA expression or other protein detection methods

• Genetic validation:

  • siRNA/shRNA knockdown to demonstrate reduced signal

  • CRISPR/Cas9 knockout as gold standard for specificity

  • Overexpression systems to confirm detection of increased protein levels

• Blocking/competition experiments:

  • Pre-incubate antibody with immunizing peptide or recombinant protein

  • Observe reduction or elimination of specific signal

• Documentation and reporting:

  • Maintain detailed records of validation experiments

  • Include validation data in publications, even as supplementary information

  • Specify exact clone, catalog number, and lot when reporting antibody use

The increasing focus on antibody validation in the research community has led to initiatives for improving reproducibility. Market analysis shows leading antibody companies like Cell Signaling Technology, Thermo Fisher Scientific, and Abcam emphasizing validation data for their products .

How can I resolve weak or absent signal when using RXR beta/NR2B2 antibodies in Western blotting?

When encountering weak or absent signals in Western blotting:

• Sample preparation assessment:

  • For nuclear receptors like RXR beta/NR2B2, verify nuclear extraction efficiency

  • Include protease inhibitors to prevent degradation

  • Verify protein concentration using reliable quantification methods

• Transfer efficiency verification:

  • Use reversible protein stains to confirm successful transfer

  • Optimize transfer conditions for your protein size range

  • Consider membrane type (PVDF often provides better sensitivity than nitrocellulose)

• Antibody-specific considerations:

  • Check antibody storage conditions (PP-H7341-00 should be stored at -70°C)

  • Verify antibody viability using known positive control samples

  • Test increased antibody concentration or longer incubation times

• Detection system optimization:

  • Ensure secondary antibody compatibility with your primary antibody

  • Increase exposure time for chemiluminescence detection

  • Consider more sensitive detection methods or signal amplification systems

• Protein expression verification:

  • Confirm expected expression in your samples using RT-qPCR

  • Consider cell type-specific expression patterns

  • Check literature for expected protein levels in your experimental system

A systematic approach to troubleshooting will help identify the most likely cause of detection failure.

What strategies can address high background in immunofluorescence when using RXR beta/NR2B2 antibodies?

High background in immunofluorescence can obscure specific signals:

• Antibody optimization:

  • Titrate primary antibody concentration (typically test 2-5 dilutions)

  • Consider longer incubation times at lower antibody concentrations

  • Evaluate different fixation protocols that may affect epitope accessibility

• Blocking optimization:

  • Test different blocking agents (BSA, normal serum, commercial blockers)

  • Increase blocking time (1 hour to overnight)

  • Add 0.1-0.3% Triton X-100 to blocking solution to reduce non-specific hydrophobic interactions

• Washing optimization:

  • Increase number and duration of washes

  • Include mild detergents in wash buffers

  • Maintain consistent buffer composition throughout the protocol

• Fixation considerations:

  • Overfixation can increase background through autofluorescence

  • Test reduced fixation times

  • Consider alternative fixatives that may preserve epitope structure

• Autofluorescence reduction:

  • For tissues with high autofluorescence, consider Sudan Black B treatment

  • Photobleaching before antibody incubation

  • Use long-wavelength fluorophores that avoid autofluorescence range

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Reduce secondary antibody concentration

  • Ensure secondary antibody specificity for the primary antibody host species

These approaches should be systematically tested to determine which factors most significantly contribute to background in your specific experimental system.

How can I optimize co-immunoprecipitation experiments to detect weak or transient RXR beta/NR2B2 interactions?

Detecting weak or transient interactions in co-immunoprecipitation experiments requires specialized approaches:

• Stabilization of interactions:

  • Consider in vivo crosslinking with cell-permeable crosslinkers (e.g., DSP, formaldehyde)

  • Optimize crosslinking conditions to balance capture efficiency with epitope preservation

  • Use reversible crosslinkers if subsequent analysis requires native proteins

• Buffer optimization:

  • Reduce salt concentration to preserve weak interactions (100-120 mM NaCl)

  • Test different detergent types and concentrations

  • Include stabilizing agents (glycerol 5-10%)

  • Maintain constant cold temperature throughout procedure

• Antibody considerations:

  • Use excess antibody to ensure complete capture of target protein

  • Consider directly conjugated antibodies to eliminate background from IgG chains

  • Test different orientations of co-IP (i.e., precipitate with antibodies against either protein)

• Detection enhancements:

  • Use highly sensitive detection methods for Western blotting

  • Consider mass spectrometry for unbiased identification of interacting partners

  • Verify interactions with alternative methods (proximity ligation assay, FRET)

• Controls for validation:

  • Include stringent negative controls (IgG, irrelevant antibodies)

  • Use cells lacking one interaction partner as negative control

  • Create positive controls by co-expressing known interacting partners

Recent advances in antibody technology, including the development of bispecific antibodies for targeted applications, demonstrate how antibody engineering can enhance detection capabilities for challenging protein interactions .